PedAM
Pediatric Disease Annotations & Medicines
| Disease | hepatitis |
| Symptom | C0040034|thrombocytopenia |
| Sentences | 36 |
| PubMedID- 24457056 | We report the case of a 51 - year – old caucasian female who developed a severe, reversible, immune thrombocytopenia associated with hepatitis c virus infection. |
| PubMedID- 24128106 | Eltrombopag for the treatment of thrombocytopenia in patients with chronic hepatitis c: two case reports. |
| PubMedID- 25209590 | Severe thrombocytopenia in a patient with hepatitis c treated with eltrombopag from off-label drug use to on-label drug use: a case report. |
| PubMedID- 20308017 | Severe thrombocytopenia associated with acute autochthonous hepatitis e. |
| PubMedID- 19689996 | thrombocytopenia in patients with chronic hepatitis c: a possible role of hcv on platelet progenitor cell maturation. |
| PubMedID- 22312391 | However, thrombocytopenia also occurs in patients with chronic hepatitis c without cirrhosis. |
| PubMedID- 24304453 | thrombocytopenia in patients with chronic hepatitis c may represent an obstacle for the initiation of antiviral treatment. |
| PubMedID- 24531177 | Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis c virus infection: a new option for clinicians. |
| PubMedID- 20796207 | Epidemiology of thrombocytopenia in patients with chronic hepatitis c: more than meets the eye. |
| PubMedID- 24047408 | The aim of this study was to determine whether abnormalities in the ipf were associated with thrombocytopenia in patients with hepatitis b virus-related chronic hepatitis (chb). |
| PubMedID- 20460556 | Objective: to review the pharmacology and pharmacokinetics and evaluate the safety and efficacy of eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (itp) and thrombocytopenia associated with hepatitis c virus (hcv) cirrhosis. |
| PubMedID- 25764686 | thrombocytopenia in patients with chronic hepatitis c represents an obstacle for the initiation of antiviral treatment. |
| PubMedID- 21188328 | Background and aims: thrombocytopenia in patients with chronic hepatitis c may be the result of several factors: bone marrow inhibition, the decrease of liver thrombopoietin production and an autoimmune mechanism. |
| PubMedID- 24731162 | Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis c patients with thrombocytopenia and advanced fibrosis. |
| PubMedID- 24010032 | Adinolfi, et al showed that hepatic fibrosis and altered production of thrombopoietin are central players in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis without splenomegaly (adinolfi et al. |
| PubMedID- PMC4034027 | Recent reports suggest that certain polymorphisms in type i ifn signaling molecules are associated with ifn-induced neutropenia and thrombocytopenia in patients with chronic hepatitis c. ifnγ binds to a cell-surface receptor composed of two transmembrane polypeptides ifgr1 and ifgr2 resulting in activation of the janus kinases jak1 and jak2, phosphorylation of stat1, formation of stat1 homodimers, and activation of a specific set of genes that encode the effector molecules responsible for mediating its biological activity. |
| PubMedID- 20796208 | Prevalence of thrombocytopenia among patients with chronic hepatitis c: a systematic review. |
| PubMedID- 20362495 | The mortality rate was 6/95 (6.3%) in patients who developed plasma leakage, 3/42 (7.1%) in patients who developed hepatitis, 5/93 (5.4%) in patients with severe thrombocytopenia, and 3/12 (25%) in the patients who demonstrated together all these severe manifestations. |
| PubMedID- 26417629 | Eltrombopag (revolade ) and thrombocytopenia in patients with hepatitis c. |
| PubMedID- 23995112 | Eltrombopag is effective for the treatment of chronic hepatitis with thrombocytopenia, and portal vein thrombosis at this time has rarely been reported. |
| PubMedID- 24653754 | In november 2012, the us food and drug administration (fda) approved eltrombopag (promacta), an oral thrombopoietin agonist, for treatment of thrombocytopenia in patients with chronic hepatitis c to allow the initiation and maintenance of ifn-based therapy. |
| PubMedID- 24714308 | Another recent study concluded that anti-p antibodies contribute to thrombocytopenia associated with chronic hepatitis c virus infection . |
| PubMedID- 23671722 | Conclusion: attention should be paid to potential thrombocytopenia in the treatment of chronic hepatitis c patients. |
| PubMedID- 20805953 | The increase in platelet counts after pse may also improve the svr rate in chronic hepatitis c patients with thrombocytopenia . |
| PubMedID- 24696622 | Many recent studies have suggested a potential role for this novel agent in the treatment of thrombocytopenia associated with hepatitis-c infection. |
| PubMedID- 25728497 | Background: there are many potential causes of thrombocytopenia in patients with chronic hepatitis c (chc). |
| PubMedID- 24621321 | We report a case of severe thrombocytopenia that developed in a patient with chronic hepatitis c treated with pegylated interferon combined with ribavirin in spite of having the inosine triphosphatase-cc genotype. |
| PubMedID- 25886818 | Eltrombopag received accelerated fda approval in the united states for the treatment of patients with chronic idiopathic thrombocytopenic purpura (itp) in 2008 and full approval in 2011. eltrombopag has been shown to effectively increase platelet counts and reduce thrombocytopenia-associated complications in patients with itp and hepatitis c . |
| PubMedID- 20731135 | This article represented a modern view on the problem of thrombocytopenia in patients with chronic hepatitis c, including it's role as an adverse event of antiviral therapy. |
| PubMedID- 20720351 | A case of severe thrombocytopenia in a patient with chronic hepatitis c caused by a single administration of pegylated interferon alpha 2a subsequent to 48 weeks of pegylated interferon alpha 2b plus ribavirin therapy. |
| PubMedID- 23857723 | Laboratory investigation revealed severe acute hepatitis with thrombocytopenia and coagulopathy. |
| PubMedID- 23001404 | Improvement of thrombocytopenia in hepatitis c-related advanced fibrosis patients after sustained virological response. |
| PubMedID- 26364898 | Recent studies have suggested a potential role of eltrombopag in the treatment of thrombocytopenia associated with hepatitis-c virus infection. |
| PubMedID- 25331767 | Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis c. |
| PubMedID- 21120192 | Suggested that thrombocytopenia in patients with hepatitis c infection may be due to a variety of non-immune and immune mechanisms . |
| PubMedID- 26278293 | Association of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome with immune thrombocytopenia and graves' disease. |
Page: 1